Health and Fitness Health and Fitness
Wed, August 24, 2011
Tue, August 23, 2011
Mon, August 22, 2011

Forest Receives Report from Inspector of Election on Voting at August 18 Annual Meeting


Published on 2011-08-22 14:27:04 - Market Wire
  Print publication without navigation


NEW YORK--([ BUSINESS WIRE ])--Forest Laboratories, Inc. (NYSE: FRX) (aForesta) today announced that the preliminary report of IVS Associates, Inc., the independent inspector of elections for the Companya™s Annual Meeting, confirms that all ten of Foresta™s Board nominees were elected by a substantial majority.

Based on the IVS report of the preliminary voting results, the ten Company nominees were elected to the Forest Board of Directors, each receiving more than a majority of all outstanding shares. Over 226 million votes, or approximately 98% of the votes cast in the election, were voted for each of the six Forest nominees that had not been contested. With regard to the four contested seats, the Forest nominees were elected by wide margins. Mr. Goodman and Mr. Solomon received over 169 million and 165 million votes, respectively, and Messrs. Goldwasser and Salans each received over 152 million votes for their election.

According to the inspectora™s report, Icahn nominee Richard Mulligan received only 70.5 million votes in support of his election and Alex Denner, the Icahn candidate with the second highest total, received less than 49 million votes. Therefore, the margin of victory for the contested Forest nominees was 81 million votes with respect to Mr. Mulligan and 103 million votes with respect to Mr. Denner. Messrs. Bebchuk and Ende received only 42.1 million and 33.5 million votes in favor of their election, respectively. As of the 2011 Annual Meeting record date, the Icahn group held approximately 19.9 million Forest shares.

The inspectora™s preliminary report also indicates that Forest shareholders approved the advisory vote on executive compensation, supported an annual frequency for the advisory vote on executive compensation, and ratified the appointment of BDO USA, LLP as the Companya™s independent registered public accountant.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said, aWe are pleased to receive this positive news confirming the results of our ten nominees today as we launch Dailresp and Viibryd with our field sales organization. This is an important week as we move forward with two of the aNext Ninea™ products in our late-stage pipeline. We expect these high-potential products to help drive growth and diversify revenues in the years ahead.a

Based on the inspectora™s preliminary report, shareholders representing more than 231 million shares, or 83.1% of the Company's issued and outstanding common stock as of the record date, either voted by proxy or in person at the meeting. The preliminary vote count is subject to review, challenge and official certification, but is not expected to change materially, if at all.

Based on the report provided by IVS, the preliminary results were as follows:

Preliminary Voting Results a"August 22, 2011

Election of Directors For Withheld

Forest Nominees:

Howard Solomon 165,349,211 4,623,743
Nesli Basgoz, M.D. 227,451,746 3,615,456
Christopher J. Coughlin 226,635,822 4,431,380
Dan L. Goldwasser 152,002,769 1,617,812
Kenneth E. Goodman 169,301,063 671,891
Gerald M. Lieberman 227,425,851 3,641,351
Lawrence S. Olanoff 226,222,145 4,845,057
Lester B. Salans 152,935,444 685,137
Brenton L. Saunders 227,430,702 3,636,500
Peter J. Zimetbaum 227,436,483 3,630,719

Icahn Nominees:

Alexander J. Denner 48,928,220 28,518,401
Richard Mulligan 70,539,256 6,907,365
Lucian A. Bebchuk 42,126,141 1,968,107
Eric J. Ende 33,485,948 27,608,300
Advisory Vote on Executive Compensation
For Against Abstain
170,391,984 59,879,803 795,426
Frequency of Advisory Vote on Executive Compensation
1 Year 2 Years 3 years Abstain
213,927,107 748,048 15,498,979 893,078
Auditor Ratification
For Against Abstain
229,586,578 1,466,628 629,430

Forward Looking Information

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, changes in laws and regulations affecting the healthcare industry and the risk factors listed from time to time in Forest Laboratoriesa™ Annual Reports on Form 10-K (including the Annual Report on Form 10-K for the fiscal year ended March 31, 2011), Quarterly Reports on Form 10-Q, and any subsequent SEC filings.

Contributing Sources